Business Description
Prenetics Global Ltd
NAICS : 621512
SIC : 8734
ISIN : BMG686031698
Share Class Description:
PRE: Class ADescription
Prenetics Global Ltd is a diagnostic and genetic testing company. It is a genomics and precision oncology company that has devised a method to integrate early detection for cancer, targeted therapy and direct-to-consumer genetic testing services into one comprehensive platform. It operates in two segments. The prevention segment includes the design & sale of genetics testing (including update services) & stool-based DNA tests for early colorectal cancer screening. The diagnostic segment includes the sale of COVID-19 testing services & products and precision oncology services. The majority of revenue is from the diagnostics segment. Geographically, it operates in Hong Kong and the United Kingdom, out of which the majority is from Hong Kong.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 13.09 | |||||
| Equity-to-Asset | 0.81 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.7 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 1.71 | |||||
| Beneish M-Score | -2.8 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 251.9 | |||||
| 3-Year EBITDA Growth Rate | -139.7 | |||||
| 3-Year EPS without NRI Growth Rate | -82.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 16.14 | |||||
| 9-Day RSI | 24.59 | |||||
| 14-Day RSI | 29.22 | |||||
| 6-1 Month Momentum % | -28.53 | |||||
| 12-1 Month Momentum % | -62.28 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.61 | |||||
| Quick Ratio | 2.53 | |||||
| Cash Ratio | 1.71 | |||||
| Days Inventory | 11.09 | |||||
| Days Sales Outstanding | 29.71 | |||||
| Days Payable | 15.09 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.3 | |||||
| Shareholder Yield % | 16.68 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 47.52 | |||||
| Operating Margin % | 7.3 | |||||
| Net Margin % | -15.16 | |||||
| FCF Margin % | 2.8 | |||||
| ROE % | -19.85 | |||||
| ROA % | -15.44 | |||||
| ROIC % | 50.16 | |||||
| ROC (Joel Greenblatt) % | -31.75 | |||||
| ROCE % | -3.2 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio without NRI | 0.29 | |||||
| PS Ratio | 0.08 | |||||
| PB Ratio | 0.16 | |||||
| Price-to-Tangible-Book | 0.2 | |||||
| Price-to-Free-Cash-Flow | 1.99 | |||||
| Price-to-Operating-Cash-Flow | 1.1 | |||||
| EV-to-EBIT | 3.26 | |||||
| EV-to-EBITDA | 3.26 | |||||
| EV-to-Revenue | -0.08 | |||||
| EV-to-FCF | -3.02 | |||||
| Price-to-Graham-Number | 0.05 | |||||
| Price-to-Net-Current-Asset-Value | 0.65 | |||||
| Price-to-Net-Cash | 2.07 | |||||
| Earnings Yield (Greenblatt) % | 30.67 | |||||
| FCF Yield % | 23.09 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers